5.2
Impact Factor
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Corrigendum
Current Issue
Editorial
Erratum
Full Length Article
Full lenth article
Letter to Editor
Original Article
Research article
Retraction
Retraction notice
Review
Review Article
SPECIAL ISSUE: ENVIRONMENTAL CHEMISTRY
5.3
Impact Factor
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Corrigendum
Current Issue
Editorial
Erratum
Full Length Article
Full lenth article
Letter to Editor
Original Article
Research article
Retraction
Retraction notice
Review
Review Article
SPECIAL ISSUE: ENVIRONMENTAL CHEMISTRY
View/Download PDF
Original Article
ARTICLE IN PRESS
doi:
10.25259/AJC_196_2026

Translate:

Design, synthesis, and structural characterization of novel 4-aminoantipyrine derivatives: Experimental and computational insights via DFT and molecular docking

Author affiliations
Department of Chemistry, College of Science and Humanities in Al-Kharj, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.
Article History
Corresponding author(s)

* Corresponding author: E-mail address: i.filali@psau.edu.sa (I. Filali)

Article tools · PDF & citations

Abstract

4-Aminoantipyrine (4-AAP) derivatives are of significant interest in medicinal chemistry because of their diverse therapeutic potentials. In this study, we report the synthesis of five novel 4-aminoantipyrine derivatives (P1–P5). The synthetic approach involved the initial preparation of enaminone (I1) via a solvent-free reaction of 4-aminoantipyrine with acetylacetone, followed by condensation with various primary amines or hydrazides in refluxing ethanol solution. The chemical structures of the prepared compounds were characterized using mass spectrometry, FT-IR, and NMR (1H and 13C) spectroscopy. Density functional theory (DFT) calculations were performed at the B3LYP/6-311++G (d,p) level to optimize the molecular geometries and evaluate the global reactivity properties. Computational analysis revealed that the planarity of the molecules was highly dependent on the substituents of the imine moiety, with compounds P1, P4, and P5 exhibiting near-planar geometries. Furthermore, molecular docking simulations were conducted against Human DNA Topoisomerase I (PDB: 1T8I) to assess the binding affinity and potential anticancer mechanisms of the derivatives. These results were complemented by ADMET and toxicity predictions using the Swiss ADME and ProTox-3.0 platforms to evaluate their pharmacokinetic profiles and drug-like properties. This integrated experimental and theoretical study highlights the potential of these new 4-AAP derivatives as scaffolds for the development of bioactive agents.

Keywords

  • 4-aminoantipyrine derivatives
  • ADMET
  • DFT calculations
  • Human DNA Topoisomeras I
  • Molecular docking
  • Synthesis
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

1. Introduction

The structural diversity and biological importance of heterocyclic compounds make them the most significant class of compounds in organic chemistry [1,2]. A notable example is antipyrine, which incorporates a pyrazolone-based five-membered lactam ring [3,4]. This framework serves as a versatile precursor for the synthesis of Schiff bases through reactions with various aldehydes. Recent research has highlighted a broad spectrum of newly synthesized antipyrine-derived Schiff bases, emphasizing their growing importance in modern chemical synthesis [5-7].

4-aminoantipyrine (4-AAP) (Figure 1) is a prominent antipyrine derivative first synthesized by Knorr in 1883. It holds the distinction of being the first pyrazolone derivative used in the management of pain and inflammation, while exhibiting a wide range of other biological activities, including anticancer, antimicrobial, and antiviral properties [8-12]. The 4-AAP scaffold is of significant pharmacological interest because of its structural relationship with metamizole (Novalgin), a widely utilized non-opioid analgesic and antipyretic drug [13]. Metamizole is a prodrug that undergoes rapid non-enzymatic hydrolysis in the body to form its primary active metabolite, 4-methylaminoantipyrine (MAP) [14]. Recent studies have highlighted that this scaffold possesses more than just analgesic properties. For instance, metamizole has been shown to limit proliferation in chronic myeloid leukemia cells and trigger apoptosis via the Bax/Bcl-2/Caspase-3 cascade [15].

4-Aminoantipyrine.
Figure 1. 4-Aminoantipyrine.

Although the parent compound exhibits proven bioactivity, its clinical utility is frequently restricted by challenges such as unfavorable metabolism, potential toxicity profiles, and limited efficacy against highly resistant biological targets [15]. This necessity for improvement has consequently driven medicinal chemistry research toward the strategic functionalization of the 4-AAP nucleus. Efforts have primarily focused on modifying the reactive C-4 amino group to generate 4-Aminoantipyrine derivatives specifically engineered to optimize pharmacokinetic properties, enhance therapeutic potency, and introduce novel mechanisms of action [16].

Derivatives of 4-aminoantipyrine have been synthesized and studied for their diverse biological activities, including anti-inflammatory [17], antibacterial [18], anthelmintic [19], and anticancer properties [20,21].

Given the importance of 4-aminoantipyrine derivatives in the biological and therapeutic fields, we synthesized five new derivatives (P1–P5) and elucidated their structures using mass spectrometry, IR, and NMR techniques. Furthermore, the electronic properties and potential biological targets were investigated through density functional theory (DFT) calculations and molecular docking simulations.

2. Materials and Methods

2.1. Instruments and spectral measurements

Chemicals and solvents were used without further purification. Melting points were determined using the capillary tube method on a Gallenkamp melting point apparatus. A Perkin Elmer 2000 FTIR spectrometer was employed to record spectra from KBr discs across a range of 4000–400 cm⁻1. NMR data were collected using a Bruker Avance 400 MHz ultrashield system, employing TMS as an internal standard in either CDCl3 or CD3OD.

2.2. General procedures

2.2.1. General procedure for the preparation of compound I1

A mixture of 4-aminoantipyrine (3 g) and acetylacetone (3 mL) was stirred at room temperature for 20 min. The resulting yellow precipitate was collected by filtration and washed with diethyl ether to yield the corresponding enaminone I1 as a yellow solid [22].

(Z)-4-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro1H-4-pyrazolylamino)-3-penten-2-one (I1). Yellow solid, m.p. 127-129°C, yield: 92%; EI m/z 285.18. IR (KBr): ѵmax (cm-1) 1674, 1617, 1561, 1270. NMR 1H (CDCl3, 400 MHz) δH: 11.55 (s, NH), 7.48-7.41 (m, 5H), 5.24 (s, 1H), 2.86 (s, 3H), 2.66 (s, 3H), 2.15 (s, 3H), 2.14 (s, 3H). NMR 13C (CDCl3, 400 MHz) δC: 196.91 (C=O), 163.4 (C=O), 150.7 (C), 134.1 (C), 129.3 (C), 126.9 (CH), 124.1 (CH), 110.5 (C), 97.5 (CH), 36.1(CH3), 29.1 (CH3), 19.3 (CH3), 10.6 (CH3).

2.2.2. General procedure for the preparation of derivatives P1-P5

To a solution of enaminone I1 (0.1 g, 0.3 mmol) in boiling ethanol, an equimolar amount of the respective amine or hydrazine was added, catalyzed by a few drops of glacial acetic acid. The reaction mixture was heated under reflux for 24 h. Upon completion, the solvent was evaporated under vacuum, and the crude product was purified via preparative thin-layer chromatography (TLC) using an EtOAc/CH3OH solvent system to yield the desired derivatives [23].

Compound P1: 4-(((2Z,4E)-4-(2-(2,4-dinitrophenyl)hydrazono)pent-2-en-2-yl)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one:

Yellow liquid, yield: 70%; EI m/z 464.4. IR (KBr): ѵmax (cm-1) 3322, 3089, 1615, 1588, 1419, 1280. NMR 1H (CDCl3, 400 MHz) δH: 11.16 (s, NH), 9.16 (m, NH), 8.35 (m, 3H), 7.94 (m, 2H) 7.27 (m, 3H), 4.1 (s, 1H), 3.48 (m, 3H), 2.17 (s, 3H), 1.90 (s, 3H), 1.83 (s, 3H). NMR 13C (CDCl3, 400 MHz) δC: 161.1 (C=O), 152.8 (C=N), 144.9 (C), 143.4 (C), 138.2 (C), 130.2 (C), 129.4 (CH), 123.5 (CH), 116.3 (C), 58.4 (CH), 36.1 (CH3), 29.1 (CH3), 18.41 (CH3), 16.02 (CH3).

Compound P2: 1,5-dimethyl-4-(((2Z,4E)-4-(naphthalen-1-ylimino)pent-2-en-2-yl)amino)-2-phenyl-1,2-dihydro-3H-pyrazol-3-one:

Yellow liquid, yield: 58%; EI m/z 410.89. IR (KBr): ѵmax (cm-1) 3008, 1666, 1558, 1419, 1280.

NMR 1H (CD3OD, 400MHz) δH: 7.68 (m, 2H), 7.52-7.26 (m, 11H), 4.27 (m, 1H), 3.66 (s, 3H), 2.86 (s, 3H), 2.20 (s, 3H), 2.15 (s, 3H). (CD3OD, 400 MHz) δC: 167.9 (C=O), 162.0 (C=N), 138.8 (C), 134.8 (C), 132.3 (C), 130.9 (C), 129.1 (CH), 128.8 (CH), 128.7 (CH), 126.4 (C), 123.8 (CH), 118.3 (C), 65.6 (CH), 37.3 (CH3), 19.1 (CH3), 13.6 (CH3), 10.9 (CH3).

Compound P3: 4-(((2Z,4E)-4-((4-methoxyphenyl)imino)pent-2-en-2-yl)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one:

Yellow liquid, yield: 60%; EI m/z 390.40, IR (KBr): ѵmax (cm-1) 3347, 3239, 2823, 1635, 1617, 1496, 1218. NMR 1H (CD3OD and CDCl3, 400 MHz) δH: 7.77 (m, 2H), 7.43 (m, 5H), 7.26 (m, 2H), 4.22 (m, 1H), 3.74 (s, 3H), 3.39 (s, 3H), 2.36 (m, 3H), 2.26 (s, 3H), 2.08 (s, 3H). (CD3OD and CDCl3, 400 MHz) δC: 167.7 (C=O), 162.0 (C=N), 149.5 (C), 138.2 (C), 135.2 (C), 132.3 (C), 131.9 (C), 130.9 (C), 129.3 (CH), 128.7 (CH), 126.0 (CH), 122.6 (CH), 119.0 (C), 66.7 (O- CH3), 50.3 (CH), 36.6 (CH3), 19.1 (CH3), 13.9 (CH3), 11.2 (CH3).

Compound P4: 4-(((2Z,4E)-4-((2-aminoethyl)imino)pent-2-en-2-yl)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one:

Brown liquid, yield: 52%; EI m/z 327.87. IR (KBr): ѵmax (cm-1) 2915, 1650, 1496, 1280.

NMR 1H (CD3OD, 400 MHz) δH: 7.70 (m, 2H), 7.58 (m, 3H), 4.30 (m, 1H), 3.63 (s, 3H), 3.23 (m, 2H), 2.86 (s, 3H), 2.12 (s, 3H), 2.06 (s, 3H), 1.72 (m, 2H). (CD3OD, 400 MHz) δC: 166.7 (C=O), 162.0 (C=N), 138.7 (C), 134.9 (C), 130.9 (C), 129.1 (CH), 126.1 (CH), 123.3 (CH), 118.5 (C), 68.1 (CH2), 66.6 (CH), 38.7 (CH2), 36.6 (CH3), 29.6 (CH3), 18.2 (CH3),13.9 (CH3).

Compound P5: 1,5-dimethyl-2-phenyl-4-(((2Z,4E)-4-(2-phenylhydrazono)pent-2-en-2-yl)amino)-1,2-dihydro-3H-pyrazol-3-one:

Brown liquid, yield: 60%; EI m/z 375.98. IR (KBr): ѵmax (cm-1) 2962, 1650, 1617, 1561, 1265, 1085. NMR 1H (CD3OD, 400 MHz) δH: 7.70-7.28 (m, 10H), 4.29 (m, 1H), 3.24 (s, 3H), 3.11 (s, 3H), 2.25 (s, 3H), 2.12 (s, 3H). (CD3OD, 400 MHz) δC: 167.9 (C=O), 162.0 (C=N), 147 (C), 143.5 (C), 134.0 (C), 129.3 (CH), 128.8 (CH), 128.7 (CH), 127.6 (CH), 123.4 (CH), 112.4 (C), 66.6 (CH), 36.6 (CH3), 19.1 (CH3),13.9 (CH3), 10.9 (CH3).

2.3. DFT details

The synthesized compounds I1, P1-P5 were optimized using the hybrid functional B3LYP and the triple basis set 6-311++G(d,p) [24]. The optimization was followed by frequency calculations as executed in the Gaussian 16 software [25]. The optimized geometries were found to be true minima, and the calculated vibrational modes were scaled by a factor of 0.9679 [26]. The global reactivity properties were calculated using considering Koopman’s theorem [27]. The solute-solvent interactions are taken into consideration using the polarizable continuum model formalism (IEPCM), in which the solute is embedded in a cavity defined by its dielectric constant, ε (e.g., for DMSO, ε = 46.826) [28]. DFT calculations were performed using the Gaussian 16 software [25]. More information on DFT calculations and the choice of methodology may be found in some of our reported studies [29-31].

2.4. Molecular docking

The binding modes of the synthesized compounds I1, P1-P5, into the binding pocket of Human DNA Topoisomerase I, a common target of a variety of anticancer agents, have been assessed by means of the Autodock package [32,33]. Molecular docking was validated by re-docking EHD into the binding site of Human DNA Topoisomerase I, which was relatively well reproduced with an RMSD value of 0.30 Å and a binding energy of -10.50 kcalmol-1. The grid parameters of Human DNA Topoisomerase I were generated using the AutoDock Tool. The grid points x, y, and z-axes were set to 40×40×40 and centered at 21.893 -2.654 28.295. The distance between two connecting grid points was 0.375 Å. The re-docking of EHD into the binding site of the Human DNA Topoisomerase I was relatively well reproduced with an RMSD value of 0.30 Å and binding energy of -10.50 kcalmol-1. The geometric minimization of compounds I1 and P1-P5 was performed using the MMFF94 force field as a preparatory step for docking. The Lamarckian genetic algorithm was employed for the docking study, encompassing 500 runs. For each run, a population of 150 individuals was utilized, involving 250,000 energy evaluations and 27,000 generations. The weights for crossover, mutation, and elitism were maintained at 0.8, 0.02, and 1, respectively.

2.5. ADMET study

The ADMET, pharmacokinetic, and physicochemical properties of the synthesized compounds (I1, P1-P5) were estimated using the online Swiss ADME tool (http://www.swissadme.ch/). The toxicity of I1 and P1-P5 was predicted using the ProTox-3.0, an online virtual platform (https://tox.charite.de/protox3/).

3. Results and Discussion

3.1. Chemistry

In our approach to access new 4-aminoantipyrine derivatives P1-P5, we first prepared enaminone I1. Thus, 4-aminoantipyrine 1 was reacted with an excess of acetylacetone. The reaction was performed without solvent, affording enaminone (I1). The structure of compound I1 was established according to its spectral data (NMR spectra (1H, 13C) and FT-IR) and compared with those reported in the literature [21] (Scheme 1). The synthetic route was then applied to synthesize derivatives P1-P5 by condensing enaminone I1 with primary amines or hydrazides under refluxing ethanol conditions. The structures of derivatives P1-P5 were confirmed based on their spectral data (1H and 13C NMR). As an example, consider the compound (P3), the analysis of its 1H NMR spectrum primarily revealed the appearance of a new singlet at δH 3.66 ppm (3H, s) attributed to the methoxy group protons. Additionally, two massifs at δH 7.26 ppm and 7.77 ppm were assigned to the four protons of the aromatic ring. The 13C NMR spectrum confirmed the structure of P3 through the appearance of a new signal at δC 66.7 ppm (methoxy group) and a set of signals in the range of 122.6–149.5 ppm, which are characteristic of the newly introduced aromatic carbons.

Syntheses of derivatives P1-P5.
Scheme 1. Syntheses of derivatives P1-P5.

3.2. Optimized geometries and global properties of I1, P1-P5

The optimized geometries of I1 and P1-P5 are shown in Figure 2. The obtained products P1-P5 have the same basic skeleton ((Z)-4-((4-iminopent-2-en-2-yl)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one) with different substitutions in the imine moiety (Scheme 1). It is worth noting that the planarity between the substituted groups and imine moiety depends on the substituent itself. The substituted groups 2,4-dinitroaniline in P1, ethanamine in P4, and aniline in P5 yielded approximately planar geometries for the imine moiety, with torsion angles ranging from 2° to 10°. Instead, the substituted naphthalene in P2 and anisole in P3 were out of the imine plane with torsion angles of 64 and 60°, respectively. In addition, the nature of the substituted moiety, its planarity (in/out of plane) may have a strong effect on its electronic and molecular properties, and thus its reactivity and biological activity.

Optimized molecular geometries of the synthesized compounds I1, P1-P5.
Figure 2. Optimized molecular geometries of the synthesized compounds I1, P1-P5.

The calculated global reactivity properties of I1 and P1-P5 are summarized in Table 1. The calculated descriptors indicated that t the effects of the substituted moiety depend on the calculated property itself and its planarity with respect to the imine moiety. The dipole moment reflects the solubility of a compound in water. Its magnitude depends on the type of substituted moiety and the presence of heteroatoms. P1 with a 2,4-dinitroaniline moiety exhibited the highest dipole moment of 22.41 Debyes, indicating its high solubility in water. The calculated energy gap (Egap) may indicate (i) the reactivity, softness, and stability of the synthesized compounds. Compounds with low gap energies are considered soft compounds, i.e., these molecules can be polarized more easily[34]. P1 has the lowest gap energy value, indicating its high reactivity and ability to be easily polarized. The polarizability of P1 and its high reactivity may be due to the presence of nitro groups in the 2,4-dinitroaniline moiety and its planarity with respect to the imine group. The stability of P1 may also be confirmed by its lowest, more negative electronic energy of -1611.79 Hartree. The effects of each global reactivity property, such as ionization potential (I ˜ -EHOMO), electron affinity (A ˜ -ELUMO), electronegativity (χ), absolute hardness (η), and softness (S), also depend on the type of substituted moiety and its geometric arrangement (Table 1). For instance, P1 displays the highest electronegativity, which indicating its ability to act as a strong nucleophile (Table 1).

Table 1. Calculated quantum chemical parameters of the synthesized compounds I1, P1-P5.
Parameters I1 P1 P2 P3 P4 P5
aIP 6.05 5.52 5.45 5.26 5.42 4.88
bEA (eV) 1.26 3.13 1.47 1.18 1.11 1.12
cEGap (eV) 4.79 2.39 3.98 4.08 4.31 3.77
d χ (eV) 3.65 4.32 3.46 3.22 3.26 3.00
eη (eV) 4.79 2.39 3.98 4.08 4.31 3.77
fS (eV-1) 0.10 0.21 0.13 0.12 0.12 0.13
gω (eV) 1.39 3.91 1.51 1.27 1.24 1.20
hµ (D) 13.50 22.41 5.61 9.09 5.86 10.96
eE (au) -936.09 -1611.79 -1300.98 -1261.80 -1050.20 -1202.64
Ionization potential, bElectronic affinity, cEnergy gap between highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital, dElectronegativity, eChemical hardness, fSoftness, gElectrophilicity, hDipole moment, and eElectronic energy.

3.3. Molecular docking results

Molecular docking was performed to estimate the binding affinity of I1, P1-P5, into the binding pocket of Human DNA Topoisomerase I, a common target of a variety of anticancer agents. Certainly, the binding affinity of P1-P5 may depend on the substituted imine moieties (Figure S1 and Scheme 1). Figure S1 displays the 3D and 2D binding interactions of the synthesized compounds I1, P1-P5 from one side and the amino acid residues of human DNA Topoisomerase I. To shed light on the estimated anticancer activity of P1-P5, the binding interactions of P1-P5 and I1, the starting material within the Human DNA Topoisomerase I binding site, were identified. Table 2 summarizes the estimated free binding energies, number of hydrogen bonds, number of residues, and amino acids involved the interactions in the complexes formed between I1, P1-P5, and the active residues of Human DNA Topoisomerase I.

Figure S1
Table 2. Free binding energies (BE in kcal/mol), hydrogen bonding (HBs), and number of closest residues (NRs) to the docked compounds I1, P1-P5 into the binding site of the Human DNA Topoisomerase I.
Compounds BE HBs NRs Amino acids involved in intermolecular interactions
I1 -8.00 2 7 ASP A533, ASN A722, LEU A721, DA D113, DT B10, TGB C11
P1 -11.47 3 7 ARG A364, HIS A362, DA D113, DT B10, DC D112, DG C12, TGB C11
P2 -10.71 2 5 ARG A364, LYS A425, DA D113, DT B10, TGB C11
P3 -11.22 3 6 ARG A364, LYS A425, THR A718, DA D113, DT B10, TGB C11
P4 -11.85 2 5 ARG A364, LYS A425, DA D113, DT B10, TGB C11
P5 -9.93 2 7 ASP A533, ASN A722, THR A718, DA D113, DT B10, DG C12, TGB C11
Topotecan -10.84 3 8 ASP A533, ASN A722, ARG A364, TGB C11, DA D113, DC D112, GLU A356, DT B10
Irinotecan -11.41 2 5 THR A718, DA D113, TGB C11, DT B10, MET A428

Molecular docking outputs revealed that I1, P1-P5 fit well within the Human DNA Topoisomerase I binding site. The I1, P1-P5 yield stable complexes with the amino acids I1, P1-P5, with relative binding energies ranging from -8.00 to -11.85 kcal mol-1. The negative binding energy might indicate that the inhibition process was spontaneous and thermodynamically favorable (Table 2). Figure S1 displays the 3D and 2D binding interactions of I1, P1-P5, within the Human Topoisomerase I binding site. The final products (P1-P5) displayed better estimated binding affinity to the Human Topoisomerase I binding site compared to the starting material I1, with a maximum variation of binding energy of 3.85 kcal/mol (Table 2 and Figure S1). Final products exhibited a maximum variation of binding energy 1.9 kcal/mol relative to the stable complex formed between P4 (substituted with ethanamine) and the Human DNA Topoisomerase I. Such a difference may be considered negligible, thus BEs may not be considered as a strong variable to distinguish between the estimated binding affinities of P1-P5. Other parameters, such as the number of HBs and the number and type of residues that interact with the docked compounds, can be used to differentiate between the estimated binding affinities. Among all the final products, P1 displayed the highest number of HBs and NRs established in the P1-Human DNA Topoisomerase I complex. Thus, it can be estimated that P1 has the strongest binding affinity compared to P1-P5. Figure 3 illustrates 3D and 2D binding interactions of P1 into the binding site of the Human Topoisomerase I. It is important to illustrate that in P1-P5, the aminopyrine moiety displayed some important interactions with the amino acids of topoisomerase I (Figures S1 and S2). P1-P5 derivatives show comparable binding affinities to topotecan and irinotecan Topoisomerase I inhibitors (Table 2 and Figure S2). In terms of binding energies, the synthesized derivative P4 yields a stable complex compared to those formed with topotecan and irinotecan topoisomerase I inhibitors of variation energies of 1.01 and 0.44 kcal/mol, respectively (Table 2).

Figure S2
3D (left) and 2D (right) binding interactions of P1 into the binding site of the Human Topoisomerase I.
Figure 3. 3D (left) and 2D (right) binding interactions of P1 into the binding site of the Human Topoisomerase I.

To emphasize the effect of the calculated electronic and molecular descriptors of I1, P1-P5 on their corresponding binding affinities towards Human Topoisomerase I, single and multiple linear regression analyses have been carried out. Table S1 summarizes the calculated correlation coefficients (R2) and standard deviations (SD) of simple linear regression curves between each calculated electronic and molecular property of I1, P1-P5, and their corresponding binding affinities towards topoisomerase I. The influence of calculated descriptors depends on the calculated property itself. IP, gap energy, hardness, softness, and electronic energy show moderate influences on the estimated binding energies, with a maximum correlation coefficient of 31.28% obtained for the electronic energy parameter (Table S1). Using forward selection, backward elimination, and step regression modes in a multiple linear regression model, and considering only the descriptors showing higher SLR correlation coefficients than 20%. The best model was obtained with the ionization potential, gap energy, electronegativity, and electronic energy descriptors which yielded a multiple linear regression curve with a correlation coefficient of 98.39% and a standard deviation of 0.4 (Figure S3).

Figure S3

Tables S1-S8

3.4. ADMET study results

The estimated physicochemical and ADMET properties of I1, P1-P5 are summarized in Tables S2-S7. All compounds obeyed Lipinski’s rule of five (Table S5). The lipophilicity (Clog P) values varied in the range of 2.00 to 5.00 (Table S3), indicating that those with Clog P of less than 2.50 are highly lipophilic. The calculated topological surface areas (TPSAs) are listed in Table S1. P3 has a TPSA within the range of 78-125 Å2 (Table S2), which may account for its high oral absorption with a relatively good bioavailability score of 0.55 (Table S5). Figure 4 shows the bioavailability radars of I1 and P1-P5. Except for the insaturation property, all other estimated properties of P1 and P2 fit inside the pink area of the polygons, which may confirm their good oral bioavailability (Figure 4). The pharmacokinetic properties indicate that I1, P1-P5 may have high GI absorption (Table S6).

Bioavailability radars of the synthesized compounds I1, P1-P5.
Figure 4. Bioavailability radars of the synthesized compounds I1, P1-P5.

Figure 5 displays the Boil-egg of the synthesized compounds I1, P1-P5. Except for P3, all compounds may penetrate the Blood-Brain Barrier (BBB). All I1, P1-P5 may have high skin permeability with log Kp < −2.5 (Table S6).

Boil-egg of the synthesized compounds I1, P1-P5.
Figure 5. Boil-egg of the synthesized compounds I1, P1-P5.

The predicted toxicity of I1, P1-P5, is assessed using the ProTox-3.0 and pkCSM, virtual platforms for the prediction of toxicities of small molecules (https://tox.charite.de/protox3/). Figure S2 and Table S8 display the toxicity radar charts for I1, P1-P5. Each axis in the radar chart represents a toxicity and its endpoint. It is worth noting that the far points from the center of each axis indicate high toxicity, while those closer to the center indicate low toxicity (Figure S2).

4. Conclusions

In summary, this study successfully synthesized five novel 4-aminoantipyrine (4-AAP) derivatives (P1–P5), confirmed by comprehensive spectroscopic analysis. DFT calculations revealed that the molecular planarity and chemical reactivity were significantly influenced by the imine moiety substituents, with P1 showing the highest potential water solubility and reactivity. Molecular docking demonstrated that all derivatives have a strong binding affinity for Human DNA Topoisomerase I, a key target for anticancer therapy, with P1 emerging as the most effective potential inhibitor. Furthermore, ADMET and toxicity evaluations confirmed that these compounds generally follow Lipinski’s rule of five and exhibit high gastrointestinal absorption and skin permeability. These findings highlight the potential of these 4-AAP derivatives as promising scaffolds for future drug development in the field of anticancer research. Future research directions will focus on conducting in-vitro enzymatic assays, against Topoisomerase I and COX-2, to experimentally validate their inhibitory concentrations (IC50) and therapeutic safety profiles.

Acknowledgment

The author extends her appreciation to Prince Sattam bin Abdulaziz University for funding this research work through the project number (PSAU/2025/03/35541).

CRediT authorship contribution statement

Insaf Filali: Conceptualization, methodology, synthesis, characterization, computational studies, formal analysis, writing original draft.

Declaration of competing interest

There are no conflicts of interest.

Declaration of generative AI and AI-assisted technologies in the writing process

The author confirm the use of AI during the preparation of this work the author used Gemini/Google in order to improve language and readability. After using this tool/service, the author reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

Supplementary data

Supplementary material to this article can be found online at https://dx.doi.org/10.25259/AJC_196_2026.

References

  1. . A review on biological and medicinal impact of heterocyclic compounds. Results in Chemistry. 2022;4:100606. https://doi.org/10.1016/j.rechem.2022.100606
    [Google Scholar]
  2. . Schiff base derivatives of 4-aminoantipyrine as promising molecules: Synthesis, structural characterization, and biological activities. Russian Journal of Bioorganic Chemistry. 2022;48:334-344. https://doi.org/10.1134/s1068162022020182
    [Google Scholar]
  3. . Schiff bases from 4‐aminoantipyrine: investigation of their in silico, antimicrobial, and anticancer effects and their use in glucose biosensor design. Bioinorganic Chemistry and Applications. 2025;2025:1-18. https://doi.org/10.1155/bca/2786064
    [Google Scholar]
  4. . Synthesis, spectroscopic characterization and antibacterial activity of new series of Schiff base derived from 4-aminoantipyrine and 2-amino benzimidazole. Zanco Journal of Medical Sciences. 2019;23:206-216. https://doi.org/10.15218/zjms.2019.026
    [Google Scholar]
  5. . Synthesis, characterization and antibacterial activity evaluation of 4-amino antipyrine derivatives and their transition metal complexes. American Journal of Bioscience and Bioengineering. 2021;9:8. https://doi.org/10.11648/j.bio.20210901.12
    [Google Scholar]
  6. . Synthesis, molecular structure and antioxidant activity of (E)-4-[Benzylideneamino]-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one, a Schiff base ligand of 4-aminoantipyrine. Journal of Chemical Crystallography. 2012;42:93-102. https://doi.org/10.1007/s10870-011-0209-1
    [Google Scholar]
  7. , , . Development of new 4-aminoantipyrine-based Schiff base compounds: Synthesis, spectral characterization, and biological evaluation. Journal of Molecular Structure. 2022;1251:131972. https://doi.org/10.1016/j.molstruc.2021.131972.
    [Google Scholar]
  8. . Synthesis, characterization and antibacterial activity of some new of novel 1,2,3-triazole-chalcone derivatives from N-Acetyl-5H-dibenzo [b,f] azepine-5-carboxamide. Nano Biomedicine and Engineering. 2019;11:99-110. https://doi.org/10.5101/nbe.v11i2.p99-110
    [Google Scholar]
  9. , . An overview of some heterocyclic organic compounds; synthesis, characterization, thermal properties and antibacterial activity. International Journal of Pharmaceutical Research. 2020;1:2394-2399. https://doi.org/10.31838/ijpr/2020.SP1.363.
    [Google Scholar]
  10. , . Recent advances in the synthesis of piperazine based ligands and metal complexes and their applications. Dalton Transactions. 2021;50:785-800. https://doi.org/10.1039/d0dt03569f
    [Google Scholar]
  11. , , . Design, synthesis, and biological screening of new 4-aminoantipyrine derivatives as potential antimicrobial and antioxidant agents. Molecules. 2023;28:1402. https://doi.org/10.3390/molecules28031402
    [Google Scholar]
  12. . Synthesis characterization and antibacterial studies of 4-aminoantipyrine Schiff’s bases. International Journal of Applied Pharmaceutical Sciences and Research. 2017;2:8-14. https://doi.org/10.21477/ijapsr.v2i1.6908
    [Google Scholar]
  13. , , . Pain management and analgesics used in small mammals during post-operative period with an emphasis on metamizole (Dipyrone) as an alternative medication. Molecules. 2022;27:7434. https://doi.org/10.3390/molecules27217434
    [Google Scholar]
  14. . Metamizole-induced agranulocytosis (MIA): A mini review. Molecular and Cellular Pediatrics. 2023;10:1-7. https://doi.org/10.1186/s40348-023-00160-8
    [Google Scholar]
  15. . Metamizole limits proliferation in chronic myeloid leukemia cells and triggers apoptosis via the bax/bcl-2/caspase-3 cascade. Medical Oncology. 2025;42:288. https://doi.org/10.1007/s12032-025-02842-x
    [Google Scholar]
  16. , , , , , . Synthesis, crystal structure, vibration spectral, and DFT studies of 4-aminoantipyrine and its derivatives. Molecules. 2013;18:877-893. https://doi.org/10.3390/molecules18010877
    [Google Scholar]
  17. , , , , . Novel Schiff base scaffolds derived from 4‐aminoantipyrine and 2‐hydroxy‐3‐methoxy‐5‐(phenyldiazenyl)benzaldehyde: Synthesis, antibacterial, antioxidant and anti‐inflammatory. Journal of Molecular Recognition. 2022;35:e2976. https://doi.org/10.1002/jmr.2976
    [Google Scholar]
  18. . Bio-important antipyrine derived Schiff bases and their transition metal complexes: Synthesis, spectroscopic characterization, antimicrobial, anthelmintic and DNA cleavage investigation. Journal of Molecular Structure. 2017;1127:314-321. https://doi.org/10.1016/j.molstruc.2016.07.123
    [Google Scholar]
  19. , . Synthesis and biological activities of 4-aminoantipyrine derivatives derived from Betti-type reaction. ISRN Organic Chemistry. 2014;2014:1-7. https://doi.org/10.1155/2014/639392
    [Google Scholar]
  20. , , . Synthesis, characterization and anti-breast cancer activity of new 4-aminoantipyrine-based heterocycles. International Journal of Molecular Sciences. 2014;15:7539-7553. https://doi.org/10.3390/ijms15057539
    [Google Scholar]
  21. , , . 4-Aminoantipyrine in carbohydrate research: Design, synthesis and anticancer activity of thioglycosides of a novel class of 4-aminoantipyrines and their corresponding pyrazolopyrimidine and pyrazolopyridine thioglycosides. Tetrahedron. 2017;73:5853-5861. https://doi.org/10.1016/j.tet.2017.08.019.
    [Google Scholar]
  22. . Structural studies of 4-aminoantipyrine derivatives. Journal of Molecular Structure. 2005;752:32-39. https://doi.org/10.1016/j.molstruc.2005.05.016
    [Google Scholar]
  23. . Synthesis, characterization, antibacterial and anticancer activities of some heterocyclic imine compounds. Journal of Molecular Structure. 2023;1289:135789. https://doi.org/10.1016/j.molstruc.2023.135789
    [Google Scholar]
  24. Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Scalmani, G., Barone, V., Mennucci, B., Petersson, G. A., Nakatsuji, H., Caricato, M., Li, X., Hratchian, H. P., Izmaylov, A. F., Bloino, J., Zheng, G., Sonnenberg, J. L., Hada, M., Ehara, M., Toyota, K., Fukuda, R., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Nakai, H., Vreven, T., Montgomery, J. A., Jr., Peralta, J. E., Ogliaro, F., Bearpark, M., Heyd, J. J., Brothers, E., Kudin, K. N., Staroverov, V. N., Kobayashi, R., Normand, J., Raghavachari, K., Rendell, A., Burant, J. C., Iyengar, S. S., Tomasi, J., Cossi, M., Rega, N., Millam, J. M., Klene, M., Knox, J. E., Cross, J. B., Bakken, V., Adamo, C., Jaramillo, J., Gomperts, R., Stratmann, R. E., Yazyev, O., Austin, A. J., Cammi, R., Pomelli, C., Ochterski, J. W., Martin, R. L., Morokuma, K., Zakrzewski, V. G., Voth, G. A., Salvador, P., Dannenberg, J. J., Dapprich, S., Daniels, A. D., Farkas, O., Foresman, J. B., Ortiz, J. V., Cioslowski, J., Fox, D. J. 2009. Gaussian 09, Revision A.02. Gaussian, Inc., Wallingford, CT.
  25. , , . Predictive computational modeling of heterocyclic derivatives: Assessing reactivity and solute-solvent interactions using PCM formalism. Inorganica Chimica Acta. 2024;560:121822. https://doi.org/10.1016/j.ica.2023.121822.
    [Google Scholar]
  26. , . New scale factors for harmonic vibrational frequencies using the b3lyp density functional method with the triple-ζ basis set 6-311+G(d,p) The Journal of Physical Chemistry A. 2005;109:2937-2941. https://doi.org/10.1021/jp045733a
    [Google Scholar]
  27. , , . Validation of Koopmans’ theorem for density functional theory binding energies. Physical Chemistry Chemical Physics. 2015;17:4015-4019. https://doi.org/10.1039/c4cp05434b
    [Google Scholar]
  28. , , . Quantum mechanical continuum solvation models. Chemical Reviews. 2005;105:2999-3094. https://doi.org/10.1021/cr9904009
    [Google Scholar]
  29. . Synthesis, spectroscopic characterizations, photophysical properties and DFT studies of a novel iridium(III) complex containing 2-(2-butoxy-4-fluorophenyl)pyridine ligand. Inorganica Chimica Acta. 2023;558:121757. https://doi.org/10.1016/j.ica.2023.121757
    [Google Scholar]
  30. . Nano-synthesis, spectroscopic characterization, quantum chemical calculations, thermal properties and antimicrobial activity of (E)-N′-(2-hydroxybenzylidene)morpholine-4-carbothiohydrazide ligand and its metal complexes. Inorganica Chimica Acta. 2020;500:119221. https://doi.org/10.1016/j.ica.2019.119221
    [Google Scholar]
  31. . Co2+ and Ni2+ Complexes of the New (E)‐N′‐(2‐hydroxy‐5‐nitrobenzylidene) morpholine‐4‐carbothiohydrazide chelating agent: Synthesis, spectral, thermal, and corrosion inhibition investigations. Applied Organometallic Chemistry. 2025;39:e70179. https://doi.org/10.1002/aoc.70179
    [Google Scholar]
  32. . AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry. 2009;30:2785-2791. https://doi.org/10.1002/jcc.21256
    [Google Scholar]
  33. , , , , , , . Structures of three classes of anticancer agents bound to the human topoisomerase I−DNA covalent complex. Journal of Medicinal Chemistry. 2005;48:2336-2345. https://doi.org/10.1021/jm049146p
    [Google Scholar]
  34. . Vibrational spectra (FT-IR, FT-Raman), frontier molecular orbital, first hyperpolarizability, NBO analysis and thermodynamics properties of piroxicam by HF and DFT methods. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2015;138:447-459. https://doi.org/10.1016/j.saa.2014.11.040
    [Google Scholar]
Show Sections